FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961122009> ?p ?o ?g. }

• W2961122009 abstract "Abstract Since the discovery of gain-of-function mutations in the tricarboxylic acid (TCA) cycle enzyme isocitrate dehydrogenase (IDH) and the resulting accumulation of the metabolite d-2-hydroxyglutarate (d-2HG) in several tumor entities (such as glioma, acute myeloid leukemia (AML), and cholangiocarcinoma) about 10 years ago research has focused on the tumor cell-intrinsic consequences. d-2HG acting as an oncometabolite was shown to promote proliferation, anoikis, tumorigenesis, and differentiation block of hematopoietic cells in an autocrine fashion. Although the prognostic value of the different types of IDH mutations remains controversial the development of inhibitors against mutated IDH is flourishing. On the other hand, serum levels of d-2HG proved to be a more robust adverse prognostic marker in AML and glioma. Surprisingly, until recently only few studies on the paracrine effects of this oncometabolite on the tumor microenvironment with particular focus on the innate or adaptive immunity were available. Now, three recent publications focused on the paracrine effects of tumor-derived d-2HG on T-cells in the context of AML and glioma. It was shown that T-cells are capable of efficiently taking up d-2HG in vitro , which was mirrored by 2HG-enriched T-cells exclusively found in samples from patients with IDH-mutated AML and glioma. Furthermore, all three studies describe an impairment of T-cell activation (although to different extents). The published effects could be at least partly attributed to metabolic alterations evoked by d-2HG influencing amongst others mTOR signaling, Hif-1α protein stability, the balance between aerobic glycolysis and oxidative phosphorylation, and the abundance of ATP (with according changes of AMPK activation). In the context of glioma it was further shown that IDH mutations and high d-2HG levels lead to reduced T-cell migration and consequently lowered T-cell infiltration at the tumor site. Moreover, two of the studies showed an increased frequency of FoxP3 + Tregs. Nevertheless, effects on downstream mechanisms and consequences have been differently addressed in the independent studies, and taken together the findings shed more light on the potentially targetable sites for improving therapeutic approaches. While the work by our group demonstrated profound impairments of Th17 polarization resulting from d-2HG-triggered Hif-1α protein destabilization the comprehensive analyses by Bunse et al . highlighted an inhibitory effect of d-2HG on the intracellular calcium signaling (downstream of the T-cell receptor) and an activation of AMPK signaling with resulting NFAT inhibition leading to the aforementioned activation defects. The summarized results of all three studies emphasized the importance of d-2HG not only as an autocrine but also a paracrine oncometabolite capable of shaping the tumor microenvironment in several facets adding to the common concept of tumor immune escape mechanisms. Those findings could lead to further improvements of the current targeted treatment strategies applied to patients harboring IDH mutations especially in view of the increasing importance of (combined) immune-based therapeutic approaches." @default.
• W2961122009 created "2019-07-23" @default.
• W2961122009 creator A5001563274 @default.
• W2961122009 creator A5011903306 @default.
• W2961122009 date "2019-07-01" @default.
• W2961122009 modified "2023-10-17" @default.
• W2961122009 title "Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate" @default.
• W2961122009 cites W1855948267 @default.
• W2961122009 cites W1900420098 @default.
• W2961122009 cites W1967980682 @default.
• W2961122009 cites W1975701262 @default.
• W2961122009 cites W1995675594 @default.
• W2961122009 cites W2002344508 @default.
• W2961122009 cites W2016752484 @default.
• W2961122009 cites W2018965555 @default.
• W2961122009 cites W2040827479 @default.
• W2961122009 cites W2058221507 @default.
• W2961122009 cites W2067874044 @default.
• W2961122009 cites W2078972833 @default.
• W2961122009 cites W2079999658 @default.
• W2961122009 cites W2080452140 @default.
• W2961122009 cites W2102799140 @default.
• W2961122009 cites W2111988427 @default.
• W2961122009 cites W2116676186 @default.
• W2961122009 cites W2126817554 @default.
• W2961122009 cites W2131860315 @default.
• W2961122009 cites W2132555177 @default.
• W2961122009 cites W2134061682 @default.
• W2961122009 cites W2142898716 @default.
• W2961122009 cites W2151422820 @default.
• W2961122009 cites W2162873738 @default.
• W2961122009 cites W2195565943 @default.
• W2961122009 cites W2219735937 @default.
• W2961122009 cites W2265127337 @default.
• W2961122009 cites W2327422980 @default.
• W2961122009 cites W2470315722 @default.
• W2961122009 cites W2476469796 @default.
• W2961122009 cites W2508474665 @default.
• W2961122009 cites W2520340383 @default.
• W2961122009 cites W2537440061 @default.
• W2961122009 cites W2585000600 @default.
• W2961122009 cites W2596261790 @default.
• W2961122009 cites W2605335091 @default.
• W2961122009 cites W2607103422 @default.
• W2961122009 cites W2625887862 @default.
• W2961122009 cites W2741802290 @default.
• W2961122009 cites W2750794123 @default.
• W2961122009 cites W2755776312 @default.
• W2961122009 cites W2765807143 @default.
• W2961122009 cites W2782192099 @default.
• W2961122009 cites W2784164696 @default.
• W2961122009 cites W2784734859 @default.
• W2961122009 cites W2790027255 @default.
• W2961122009 cites W2791122224 @default.
• W2961122009 cites W2808236336 @default.
• W2961122009 cites W2878436114 @default.
• W2961122009 cites W2883634139 @default.
• W2961122009 cites W2913322626 @default.
• W2961122009 doi "https://doi.org/10.20900/immunometab20190007" @default.
• W2961122009 hasPublicationYear "2019" @default.
• W2961122009 type Work @default.
• W2961122009 sameAs 2961122009 @default.
• W2961122009 citedByCount "1" @default.
• W2961122009 countsByYear W29611220092020 @default.
• W2961122009 crossrefType "journal-article" @default.
• W2961122009 hasAuthorship W2961122009A5001563274 @default.
• W2961122009 hasAuthorship W2961122009A5011903306 @default.
• W2961122009 hasBestOaLocation W29611220091 @default.
• W2961122009 hasConcept C121608353 @default.
• W2961122009 hasConcept C128240485 @default.
• W2961122009 hasConcept C1491633281 @default.
• W2961122009 hasConcept C151730666 @default.
• W2961122009 hasConcept C170493617 @default.
• W2961122009 hasConcept C181199279 @default.
• W2961122009 hasConcept C2776107976 @default.
• W2961122009 hasConcept C2777150147 @default.
• W2961122009 hasConcept C2778227246 @default.
• W2961122009 hasConcept C2779343474 @default.
• W2961122009 hasConcept C29537977 @default.
• W2961122009 hasConcept C3020616263 @default.
• W2961122009 hasConcept C502942594 @default.
• W2961122009 hasConcept C54355233 @default.
• W2961122009 hasConcept C55493867 @default.
• W2961122009 hasConcept C555283112 @default.
• W2961122009 hasConcept C7876069 @default.
• W2961122009 hasConcept C81885089 @default.
• W2961122009 hasConcept C86803240 @default.
• W2961122009 hasConceptScore W2961122009C121608353 @default.
• W2961122009 hasConceptScore W2961122009C128240485 @default.
• W2961122009 hasConceptScore W2961122009C1491633281 @default.
• W2961122009 hasConceptScore W2961122009C151730666 @default.
• W2961122009 hasConceptScore W2961122009C170493617 @default.
• W2961122009 hasConceptScore W2961122009C181199279 @default.
• W2961122009 hasConceptScore W2961122009C2776107976 @default.
• W2961122009 hasConceptScore W2961122009C2777150147 @default.
• W2961122009 hasConceptScore W2961122009C2778227246 @default.
• W2961122009 hasConceptScore W2961122009C2779343474 @default.
• W2961122009 hasConceptScore W2961122009C29537977 @default.
• W2961122009 hasConceptScore W2961122009C3020616263 @default.
• W2961122009 hasConceptScore W2961122009C502942594 @default.

• next